Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Operations (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Cash from Operations data on record, last reported at 123048000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 45.37% year-over-year to 123048000.0; the TTM value through Dec 2025 reached 329323000.0, up 60.66%, while the annual FY2025 figure was 329323000.0, 60.66% up from the prior year.
  • Cash from Operations reached 123048000.0 in Q4 2025 per COLL's latest filing, up from 78438000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 123048000.0 in Q4 2025 and bottomed at 25315000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 51841950.0, with a median of 58667500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: crashed 223.07% in 2022, then skyrocketed 971.63% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 36198000.0 in 2021, then soared by 83.23% to 66325000.0 in 2022, then rose by 10.57% to 73338000.0 in 2023, then grew by 15.42% to 84644000.0 in 2024, then skyrocketed by 45.37% to 123048000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 123048000.0 in Q4 2025, 78438000.0 in Q3 2025, and 72439000.0 in Q2 2025.